We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors
Read MoreHide Full Article
CRISPR Therapeutics AG (CRSP - Free Report) ended the recent trading session at $52.73, demonstrating a -6.54% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily loss of 0.4%. At the same time, the Dow lost 0.98%, and the tech-heavy Nasdaq gained 0.18%.
The stock of company has risen by 35.69% in the past month, leading the Medical sector's loss of 1.56% and the S&P 500's gain of 4.97%.
The investment community will be closely monitoring the performance of CRISPR Therapeutics AG in its forthcoming earnings report. It is anticipated that the company will report an EPS of -$1.54, marking a 3.36% fall compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $5.89 million, up 1032.88% from the year-ago period.
CRSP's full-year Zacks Consensus Estimates are calling for earnings of -$5.54 per share and revenue of $39.95 million. These results would represent year-over-year changes of -27.65% and +7.06%, respectively.
It is also important to note the recent changes to analyst estimates for CRISPR Therapeutics AG. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Currently, CRISPR Therapeutics AG is carrying a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 77, finds itself in the top 32% echelons of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors
CRISPR Therapeutics AG (CRSP - Free Report) ended the recent trading session at $52.73, demonstrating a -6.54% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily loss of 0.4%. At the same time, the Dow lost 0.98%, and the tech-heavy Nasdaq gained 0.18%.
The stock of company has risen by 35.69% in the past month, leading the Medical sector's loss of 1.56% and the S&P 500's gain of 4.97%.
The investment community will be closely monitoring the performance of CRISPR Therapeutics AG in its forthcoming earnings report. It is anticipated that the company will report an EPS of -$1.54, marking a 3.36% fall compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $5.89 million, up 1032.88% from the year-ago period.
CRSP's full-year Zacks Consensus Estimates are calling for earnings of -$5.54 per share and revenue of $39.95 million. These results would represent year-over-year changes of -27.65% and +7.06%, respectively.
It is also important to note the recent changes to analyst estimates for CRISPR Therapeutics AG. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Currently, CRISPR Therapeutics AG is carrying a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 77, finds itself in the top 32% echelons of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.